Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Covington
Fish and Richardson
Colorcon
Baxter
Citi
Johnson and Johnson
Farmers Insurance
Deloitte

Generated: February 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR POMALIDOMIDE

« Back to Dashboard

Clinical Trials for Pomalidomide

Trial ID Title Status Sponsor Phase Summary
NCT00463385 A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia Completed Celgene Corporation Phase 2 The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).
NCT00537511 A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide Terminated Celgene Corporation Phase 1/Phase 2 The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
NCT00540579 CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas Completed Celgene Corporation Phase 1/Phase 2 Because the activity of CC-4047 addresses numerous mechanisms of carcinoma growth inhibition - including, but not limited to anti-angiogenesis - CC-4047 has been selected for development as part of induction chemotherapy regimens for solid tumors. This study in pancreatic cancer is designed to determine the appropriate CC-4047 dose and regimen in combination with gemcitabine.
NCT00540579 CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas Completed SCRI Development Innovations, LLC Phase 1/Phase 2 Because the activity of CC-4047 addresses numerous mechanisms of carcinoma growth inhibition - including, but not limited to anti-angiogenesis - CC-4047 has been selected for development as part of induction chemotherapy regimens for solid tumors. This study in pancreatic cancer is designed to determine the appropriate CC-4047 dose and regimen in combination with gemcitabine.
NCT00558896 CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis Active, not recruiting National Cancer Institute (NCI) Phase 2 RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. Dexamethasone and CC-4047 may stop the growth of cancer cells by blocking blood flow to the cancer. Giving CC-4047 together with dexamethasone may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving CC-4047 together with dexamethasone works in treating patients with relapsed or refractory multiple myeloma or amyloidosis.
NCT00558896 CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis Active, not recruiting Mayo Clinic Phase 2 RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. Dexamethasone and CC-4047 may stop the growth of cancer cells by blocking blood flow to the cancer. Giving CC-4047 together with dexamethasone may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving CC-4047 together with dexamethasone works in treating patients with relapsed or refractory multiple myeloma or amyloidosis.
NCT00717522 Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma Terminated Celgene Corporation Phase 2 The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Pomalidomide

Condition Name

Condition Name for Pomalidomide
Intervention Trials
Multiple Myeloma 77
Myeloma 6
Multiple Myeloma in Relapse 6
Refractory Multiple Myeloma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Pomalidomide
Intervention Trials
Multiple Myeloma 111
Neoplasms, Plasma Cell 108
Recurrence 7
Lymphoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Pomalidomide

Trials by Country

Trials by Country for Pomalidomide
Location Trials
United States 591
Canada 69
Spain 54
Germany 42
United Kingdom 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Pomalidomide
Location Trials
California 40
New York 37
Massachusetts 32
Texas 31
Florida 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Pomalidomide

Clinical Trial Phase

Clinical Trial Phase for Pomalidomide
Clinical Trial Phase Trials
Phase 3 17
Phase 2/Phase 3 1
Phase 2 53
[disabled in preview] 80
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Pomalidomide
Clinical Trial Phase Trials
Recruiting 65
Active, not recruiting 33
Completed 21
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Pomalidomide

Sponsor Name

Sponsor Name for Pomalidomide
Sponsor Trials
Celgene Corporation 52
National Cancer Institute (NCI) 19
Celgene 18
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Pomalidomide
Sponsor Trials
Industry 136
Other 100
NIH 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
QuintilesIMS
Argus Health
Baxter
McKesson
Express Scripts
US Army
Accenture
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.